540779-29-1Relevant academic research and scientific papers
BENZOINDAZOLONE COMPOUND, AND INTERMEDIATE THEREOF
-
Paragraph 0043-0044; 0124-0125, (2022/01/12)
The present invention relates to a benzoindazolone compound, or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diasteromer, tautomer or prodrug thereof; and an intermediate thereof. A compound according to the present invention is used as a substrate for NQO1 to facilitate a redox reaction of NQO1, and thus is expected to be developable as a medicine for preventing or treating inflammatory diseases.
Synthesis of a novel pentagastrin-drug conjugate for a targeted tumor therapy
Tietze, Lutz F.,Panknin, Olaf,Major, Felix,Krewer, Birgit
experimental part, p. 2811 - 2818 (2009/04/08)
The synthesis of the novel pentagastrin seco-CBI conjugate 3, which is based on the highly cytotoxic antitumor antibiotic (+)-duocarmycin SA (1), is reported. A key step in the synthesis is the palladium-catalyzed carbonylation of aryl bromide 7 to give the benzyl ester 16, which is transformed into the new seco-CBI derivative 21 bearing a carboxylic acid ester moiety. Subsequent transformation of 21 into an activated ester followed by the introduction of ss-alanine and tetragastrin led to the new pentagastrin drug 3 that contains a peptide moiety for targeting cancer cells expressing CCK-B/gastrin receptors.
Induction of apoptosis in cancer cells
-
, (2008/06/13)
The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.
